Pharmacare
Toronto, September 7, 2022 – MORSE Consulting is delighted to announce the addition of 2 new team members, Jaclyn Beca and Sang Mi Lee who will enhance MORSE’s reimbursement expertise into pharmacoeconomics, generation and use of real world evidence (RWE) and development of innovative agreements. We are at an exciting time in drug discovery and research as new technologies, such as cell and gene therapies, offer opportunities to treat and…
Toronto, September 7, 2021 – MORSE Consulting is pleased to announce the addition of Katherine Scott as a Consultant. The Canadian public system remains one of the critical payers in this country’s pharmaceutical reimbursement pathway. This system is growing increasingly complex with new funding mechanisms for emerging gene and cell therapies, novel approaches related to outcomes-based agreements, evolving policies related to biosimilars, and variations in how provincial payers implement pCPA…
Introduction The Canadian Association for Healthcare Reimbursement (CAHR) held its first virtual Market Access 201 conference on November 24, 2020. Members of the MORSE team attended this conference and have prepared a brief summary of the key highlights. Disclaimer: Please note, this summary is based on our team’s interpretation of the discussion. Session 1. Keynote: Evolution of HTA in United States and the Impact on International Markets …
Toronto, September 9, 2020 – MORSE Consulting is pleased to announce that Sal Cimino has joined our team as Senior Consultant, Private Drug Plans. The private payer market is playing an increasingly important role in ensuring a product’s reimbursement success in Canada. With the introduction of new specialty biologics and gene therapies, private payers are turning to new cost containment strategies that strongly resemble the public payer market. Private payers…
Toronto, February 18, 2020 – MORSE Consulting is pleased to expand and strengthen our service offering with the addition of Anita Carrie and Roy Cairns. Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system. Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an issue for all stakeholders. To help…
MORSE Consulting is pleased to release a new report by Stephen Filbey of WestPAR Consulting, one of its strategic partners, entitled A Pharma industry Perspective/Opinion on British Columbia’s 2019 Budget. The NDP Government of BC, under the first non-majority legislature since 1952, has just released its second budget. With a strong economy, balanced operating budget, and an estimated $340 million in surplus over the next year, the NDP under the…
MORSE Consulting’s Managing Principal, Sherry O’Quinn, and Principal Consultant, Brad Alyward, are proud to participate in this year’s CADTH Symposium taking place from April 15-17, 2018 in Halifax, Nova Scotia. Further details on MORSE, and its strategic partner’s (Cornerstone Research Group) participation can be found below. April 16, 2018 15:15-16:30 ADT Sherry O’Quinn moderates a panel on oncology drugs with Alex Chambers (CADTH), Scott Gavura (CCO), Elena Lungu…
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
Pharmacare - Info and details on - MORSE Consulting Inc.